Mankind Pharma share analysis
Mankind Pharma passes 5 of 5 fundamental tests, a score of 10/10. On the daily chart it is in a sideways range, RSI 38, 14% below its 52-week high: range-bound: no edge either way. Its own volatility puts the likely range at ₹2,105–₹2,460 a month from now and ₹1,738–₹2,979 in a year (68% bands).
Fundamentals 10/10
- Market cap
- ₹93,988 Cr
- P/E · forward
- 46.0 · 32.1
- PEG · P/B
- — · 5.8
- ROE · net margin
- — · +14%
- Revenue · earnings growth
- +13% · +30%
- Debt / equity
- 38%
- Dividend · beta
- 0.0% · 0.4
- Next results
- 29 Oct 2026
- ✓ Net margin above 10%
- ✓ Revenue growing over 10%
- ✓ Earnings growing
- ✓ Debt/equity under 100%
- ✓ Forward P/E under trailing (earnings expected up)
Swing technicals (daily)
- Trend
- sideways · 50d above 200d
- RSI(14)
- 38
- 20 / 50 / 200-day avg
- ₹2,432 / ₹2,392 / ₹2,306
- 20-day breakout
- above ₹2,559 · below ₹2,242
- ATR(14)
- ₹64.80 (2.8% a day)
- 52-week range
- ₹1,910 – ₹2,642
- Return 3m · 6m · 1y
- -8% · +8% · -7%
What the price could do
| In | Likely range (68%) |
|---|---|
| 1 mo | ₹2,105 – ₹2,460 (-7% / +8%) |
| 3 mo | ₹1,989 – ₹2,604 (-13% / +14%) |
| 6 mo | ₹1,881 – ₹2,753 (-17% / +21%) |
| 1 year | ₹1,738 – ₹2,979 (-24% / +31%) |
Analysts (19): buy, mean target ₹2,763 (+21%)
From its own volatility (27% a year), no drift assumed: what its swings allow, not a forecast.
Mankind Pharma news · last two days
News lean: Neutral- 39h agoMankind Pharma to buy 70% of Belgian CAR-T developer for 48 million eurosThe Financial Express
- 45h agoBuzzing Stocks: Tech Mahindra surges 6% after Q2 earnings; Mankind Pharma falls 2% on Belgium acquisitionMoneycontrol
- 45h agoStocks to Watch Today, Friday, October 16, 2026: Wipro, Solar Industries, Agastya Energy & Infrastructure, Tech Mahindra, Mankind Pharmahdfcsky
- 46h agoMankind Pharma to acquire Majority Stake in Armed Cell TherapeuticsEquityBulls
- 46h agoMankind Pharma To Acquire 70% Stake In Cancer Therapy Firm ACTx, ₹511 Crore Deal Marks Entry Into Advanced Cancer TreatmentsFree Press Journal
Its order flow and footprint, the AI read of every headline, the expected move, and your own holdings beside it, with your broker connected.
Information and analytics for education only, not investment advice or a recommendation to buy or sell. Alephix Intelligence is not registered with SEBI as an investment adviser or research analyst. Prices may be delayed; figures come from public market data.